Trial reportEpilepsia2026
Early response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double-blind, placebo-controlled study in a multinational Asian population.
Trial report in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
objectiveTo examine early responses to cenobamate therapy using prospective data from a dose-response study in Asian patients with focal seizures (YKP3089C035, C035) that employed a titration regimen starting at 12.5 mg/day.
methodsIn Study C035, adults 18-70 years of age with uncontrolled focal seizures despite treatment with 1-3 antiseizure medications were randomized 1:1:1:1 to receive placebo or adjunctive cenobamate 100, 200, or 400 mg/day. The 24-week double-blind study included an 18-week titration and 6-week maintenance phase. During the first 8 weeks of titration ("early titration phase"), all cenobamate patients received the same dosing regimen: 12.5 mg/day for 2 weeks, 25 mg/day for 2 weeks, 50 mg/day for 2 weeks, and 100 mg/day for 2 weeks. Change in seizure frequency from baseline and responder rates were assessed at these 2-week intervals for combined cenobamate dose groups vs placebo. Analyses were performed on the modified intent-to-treat maintenance (MITT-M) population (≥1 study drug dose and seizure data in the maintenance phase); all patients completed early titration.
resultsOf 519 patients randomized, 446 were included in the MITT-M population (placebo n = 117, cenobamate n = 329). During Weeks 1-2, 3-4, 5-6, and 7-8 of titration, cenobamate patients experienced a median reduction in 28-day seizure frequency of 16.0% (vs 20.0% placebo, p = .81), 27.3% (vs 22.2% placebo, p = .42), 42.9% (vs 15.4% placebo, p = .002), and 55.6% (vs 20.0% placebo, p < .001), respectively. During Weeks 5-6 and 7-8, the 100% responder rates for cenobamate 50 and 100 mg/day were 17.0% (vs 12.8% placebo, p = .29) and 26.7% (vs 8.5% placebo, p < .001), respectively. SIGNIFICANCE: Statistically significant responses to cenobamate treatment occurred within the first 8 weeks of titration, including a 42.9% median reduction in 28-day seizure frequency (Weeks 5-6) and a seizure-free rate of 26.7% (Weeks 7-8). These data show that substantial seizure reductions occurred in many patients early during cenobamate titration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.